Capital Flow Monitor · Sponsors · CIK 2117806
Slate Medicines, Inc.
200 BERKELEY STREET, 18TH FLOOR, BOSTON, MA, 02116 · (617) 778-2500
Pharmaceuticals · Corporation· inc. DELAWARE true 2024
Fit score
—
Offering
$130.0M
Sold
$10.0M
% sold
7.7%
Investors
6
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-03-11 | D ·current | 506(b) | $130.0M | $10.0M | 7.7% | 6 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Andrew Levin — Director, Boston, MA
4 other raises
- Climb Bio, Inc. $110.1M of $110.1M · 100.0%
- Lonestar Medicines, Inc. $25.0M of $45.0M · 55.6%
- Imbria Pharmaceuticals, Inc. $66.7M of $144.2M · 46.3%
- Pahr Therapeutics, Inc. $4.7M of $14.0M · 33.3%
- Cindy Xiong — Director, Boston, MA
- Tim Lohoff — Director, Boston, MA
-
Neil Buckley — Executive Officer / Director, Boston, MA
1 other raise
- Pahr Therapeutics, Inc. $4.7M of $14.0M · 33.3%
- Sara Pacheco — Executive Officer, Boston, MA
- Gregory Frank Oakes — Executive Officer, Boston, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.